Regeneron Announces Investor Conference Presentation
15 nov. 2023 16h05 HE
|
Regeneron Pharmaceuticals, Inc.
TARRYTOWN, N.Y., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: Piper Sandler 35th Annual Healthcare Conference...
Regeneron Commits $34 Million Over Five Years to Continue to Sponsor the Regeneron International Science and Engineering Fair (ISEF)
13 nov. 2023 09h00 HE
|
Regeneron Pharmaceuticals, Inc.
Regeneron has sponsored ISEF - the world’s largest high school science and engineering competition, and a program of Society for Science (Society) - since 2019 Each year, over 175,000 students...
Regeneron to Highlight Scientific Advancements Across Diversified Pipeline in Difficult-to-Treat Blood Cancers and Disorders at ASH
03 nov. 2023 07h00 HE
|
Regeneron Pharmaceuticals, Inc.
Ten abstracts, including three oral presentations, spotlight the expanding body of evidence supporting odronextamab in follicular lymphoma and diffuse large B-cell lymphoma Additional presentations...
Regeneron Reports Third Quarter 2023 Financial and Operating Results
02 nov. 2023 06h30 HE
|
Regeneron Pharmaceuticals, Inc.
Third quarter 2023 revenues increased 15% to $3.36 billion versus third quarter 2022Third quarter 2023 Dupixent® global net sales (recorded by Sanofi) increased 33% to $3.10 billion versus third...
EYLEA® HD (aflibercept) Injection 8 mg Data Presentations at AAO Reinforce Efficacy and Safety Profile in Wet Age-related Macular Degeneration and Diabetic Macular Edema
01 nov. 2023 16h00 HE
|
Regeneron Pharmaceuticals, Inc.
TARRYTOWN, N.Y., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced long-term outcomes and new analyses of pivotal clinical data for EYLEA® HD...
Regeneron Shares Preliminary Results Showing Gene Therapy Improves Auditory Responses in Child with Profound Genetic Hearing Loss
26 oct. 2023 16h00 HE
|
Regeneron Pharmaceuticals, Inc.
Global Phase 1/2 CHORD trial investigating otoferlin gene therapy (DB-OTO) represents Regeneron’s first auditory program and is currently enrolling patients DB-OTO is part of a growing pipeline of...
Regeneron Announces Investor Conference Presentations
25 oct. 2023 16h05 HE
|
Regeneron Pharmaceuticals, Inc.
TARRYTOWN, N.Y., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: BMO Biopharma Spotlight Series: Oncology at 9:30...
Dupixent® (dupilumab) Phase 3 Results Show Sustained Efficacy for Up to One Year in Children 1 to 11 Years of Age with Eosinophilic Esophagitis (EoE)
22 oct. 2023 14h59 HE
|
Regeneron Pharmaceuticals, Inc.
Late-breaking presentation at ACG 2023 showed histologic and endoscopic improvements were maintained with no new safety signals to week 52 with higher dose Dupixent in these children Data reinforce...
Libtayo® (cemiplimab) Neoadjuvant Treatment Demonstrates Encouraging Event-Free Survival in Patients with Resectable Cutaneous Squamous Cell Carcinoma (CSCC)
21 oct. 2023 08h48 HE
|
Regeneron Pharmaceuticals, Inc.
89% estimated event-free survival at one year among patients with stage II to IV resectable CSCC who received Libtayo prior to surgery in a Phase 2 trial No disease recurrence among the 51% of...
Regeneron and Sanofi Provide Update on Dupixent® (dupilumab) sBLA for Chronic Spontaneous Urticaria
20 oct. 2023 17h00 HE
|
Regeneron Pharmaceuticals, Inc.
TARRYTOWN, N.Y. and PARIS, Oct. 20, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has issued a...